U.S. Markets closed

Axonics Modulation Technologies, Inc. (AXNX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
44.26+1.13 (+2.62%)
At close: 4:00PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close43.13
Open43.44
Bid44.20 x 1800
Ask44.22 x 800
Day's Range43.15 - 45.06
52 Week Range15.25 - 52.10
Volume343,675
Avg. Volume572,390
Market Cap1.762B
Beta (5Y Monthly)-0.00
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Axonics® to Participate in Piper Sandler Virtual Healthcare Conference
    Business Wire

    Axonics® to Participate in Piper Sandler Virtual Healthcare Conference

    Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation (SNM) devices for the treatment of urinary and bowel dysfunction, is scheduled to participate in the Piper Sandler Virtual Healthcare Conference on December 1-2, 2020.

  • Axonics® Announces Publication of Fecal Incontinence Study Results for Patients Treated with r-SNM® System
    Business Wire

    Axonics® Announces Publication of Fecal Incontinence Study Results for Patients Treated with r-SNM® System

    Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation (SNM) devices for the treatment of urinary and bowel dysfunction, today announced the publication of fecal incontinence study results for patients treated with the Axonics r-SNM System.

  • Axonics® Reports Third Quarter 2020 Results
    Business Wire

    Axonics® Reports Third Quarter 2020 Results

    Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation (SNM) devices for the treatment of urinary and bowel dysfunction, today reported results for the third quarter 2020.